This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
Trospium and cognition in patients with late onset Alzheimer disease
Objectives: Cholinesterase inhibitors for the treatment of Alzheimer’s Disease (AD) and antimuscarinic agents for the treatment of urge urinary incontinence (UUI) may reduce the potential effect of each other in the patients with both diseases. Trospium has a relatively low lipophilicity and low CNS penetration, and galantamine, a cholinesterase inhibitors, has also allosterically modulates nicotinic […]
Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension
Grossberg, George,
Sadowsky, Carl,
Fröstl, Hans,
Frölich, Lutz,
Nagel, Jennifer,
Tekin, Sibel,
Zechner, Stefanie,
Ros, Jacqueline,
Orgogozo, Jean-Marc
The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This was a 28-week extension to a 24-week, double-blind, double-dummy, placebo-controlled, and active-controlled study evaluating rivastigmine patches [9.5 mg/24 h (10 cm2) […]
Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study
Freund-Levi, Yvonne,
Hjorth, Erik,
Lindberg, Catharina,
Cederholm, Tommy,
Faxén-Irving, Gerd,
Vedin, Inger,
Palmblad, Jan,
Wahlund, Lars-Olof,
Schultzberg, Marianne,
Basun, Hans,
Eriksdotter-Jönhagen, Maria
Background: omega-3 fatty acids (omega-3 FAs) found in dietary fish or fish oils are anti-inflammatory agents that may influence Alzheimer’s disease (AD).; Objective: To study the effects of dietary omega-3 FA supplementation on inflammatory markers in cerebrospinal fluid (CSF) and plasma from patients with mild to moderate AD.; Methods: Thirty-five patients (70.3 +/- 8.2 years) […]
Sustained use of CPAP slows deterioration of cognition, sleep, and mood in patients with Alzheimer’s disease and obstructive sleep apnea: a preliminary study
Cooke, Jana R.,
Ayalon, Liat,
Palmer, Barton W.,
Loredo, Jose S.,
Corey-Bloom, Jody,
Natarajan, Loki,
Liu, Lianqi,
Ancoli-Israel, Sonia
Introduction: Obstructive sleep apnea (OSA) is common among patients with Alzheimer’s disease (AD). Untreated OSA exacerbates the cognitive and functional deficits. Continuous positive airway pressure (CPAP) has recently been shown to have beneficial effects on cognition in AD. Little attention has focused on the long-term benefits of CPAP in these patients.; Methods: This was an […]
Continuous positive airway pressure deepens sleep in patients with Alzheimer’s disease and obstructive sleep apnea
Cooke, Jana R.,
Ancoli-Israel, Sonia,
Liu, Lianqi,
Loredo, Jose S.,
Natarajan, Loki,
Palmer, Barton S.,
He, Feng,
Corey-Bloom, Jody
Objective: Patients with Alzheimer’s disease (AD) and obstructive sleep apnea (OSA) experience disrupted sleep. This study examined the effect of continuous positive airway pressure (CPAP) on sleep parameters in AD patients with OSA.; Methods: A randomized placebo-controlled trial of 3 weeks of therapeutic CPAP (tCPAP) vs. 3 weeks placebo CPAP (pCPAP) followed by 3 weeks […]
Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine
Brusa, Livia,
Orlacchio, Antonio,
Moschella, Vincenzo,
Iani, Cesare,
Bernardi, Giorgio,
Mercuri, Nicola Biagio
Aripiprazole (AP), a dopamine (DA) D(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington’s disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare […]
Effect of music on pain for home-dwelling persons with dementia
The purpose of this study was to investigate the effect of music on pain for home-dwelling persons with dementia. A quasiexperimental design was used. Fifteen subjects listened to their preferred music for 30 minutes before peak agitation time, for 2 days per week, followed by no music for 2 weeks. The process was repeated once. […]
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex
Marras, Connie,
Herrmann, Nathan,
Anderson, Geoffrey M.,
Fischer, Hadas D.,
Wang, Xuesong,
Rochon, Paula A.
Background: Differences between atypical antipsychotics in their potential to cause parkinsonism and risk factors for antipsychotic-induced parkinsonism are not well established. There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings.; Objective: We compared the incidence of parkinsonism after new treatment with risperidone, olanzapine, or […]
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
Olin, Jason T.,
Bhatnagar, Vinod,
Reyes, Patricio,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]